PCSK9 gene therapy (Aadigen/Divincell)

N/A

Report date: 2026/01/28 17:51:57

Base Information

Drug NamePCSK9 gene therapy (Aadigen/Divincell)

Drug Alias Namepeptide-gRNA (DIVINCELL)

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > OligonucleotideBiologics > Protein drugs > Recombinant polypeptideCell and gene therapy > Gene therapy

Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitors

TargetsProprotein convertase subtilisin kexin type 9

Therapy Area/IndicationsHyperlipoproteinemia Type IIHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesFrance

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAanastra Inc

China Registration ClassN/A

Develop Information

Active CompaniesDIVINCELL SAS Aanastra Inc

Inactive CompaniesN/A

Active IndicationsHyperlipoproteinemia Type IIHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A